Literature DB >> 11680933

Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma.

K Aoyagi1, K Kohfuji, S Yano, N Murakami, M Miyagi, J Takeda, K Shirouzu.   

Abstract

The expression of epidermal growth factor (EGF), epidermal growth factor receptor (EGFR), transforming growth factor alpha (TGF alpha), and of c-erbB-2 was immunohistochemically investigated in resected gastric carcinoma (in 39 cases of superspreading type and in 11 cases of penetrating type), to understand the differential biological features of these two types of gastric carcinoma. EGF, EGFR and c-erbB-2 positive cases were preferentially found in penetrating type rather than in superspreading type (p < 0.05, p < 0.01, and p < 0.05, respectively). The positive rates of EGFR and c-erbB-2 were significantly higher in submucosal gastric carcinoma than in intramucosal gastric carcinoma (p < 0.01, p < 0.05, respectively). These results suggested that the autocrine mechanism of the growth factors and the expression of c-erbB-2 were correlated to the degree of gastric wall invasion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680933     DOI: 10.2739/kurumemedj.48.197

Source DB:  PubMed          Journal:  Kurume Med J        ISSN: 0023-5679


  7 in total

1.  Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma.

Authors:  Ying-An Jiang; You-Yuan Zhang; He-Sheng Luo; Shou-Fu Xing
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma.

Authors:  Gui-Chao Li; Zhen Zhang; Xue-Jun Ma; Wei-Lie Gu; Ya-Nong Wang; Jin Li
Journal:  Mol Biol Rep       Date:  2011-05-11       Impact factor: 2.316

3.  Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.

Authors:  Shi-Yan Yan; Ying Hu; Jian-Gao Fan; Guo-Quan Tao; Yong-Ming Lu; Xu Cai; Bao-Hua Yu; Yi-Qun Du
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

4.  The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.

Authors:  Abbas Ghaderi; Mohammad Vasei; S A Maleck-Hosseini; Behronz Gharesi-Fard; Maliheh Khodami; Mehrnoosh Doroudchi; Helmout Modjtahedi
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

5.  Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.

Authors:  Julia Kneissl; Anja Hartmann; Nicole Pfarr; Franziska Erlmeier; Thomas Lorber; Simone Keller; Gwen Zwingenberger; Wilko Weichert; Birgit Luber
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-08       Impact factor: 4.553

6.  [The search for protein overexpression and HER2 gene amplification in gastric cancer by immunohistochemistry and in situ hybridization: experience of the CHU Hassan II of Fez].

Authors:  Hinde El Fatemi; Nawal Hammas; Karima Idrissi; Nawfel Mellas; Amal Bennani; Afaf Amarti; Anne Cayre; Frederique Penault-llorca; Omar Mesbahi
Journal:  Pan Afr Med J       Date:  2012-12-17

7.  HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Authors:  Eric Van Cutsem; Yung-Jue Bang; Feng Feng-Yi; Jian M Xu; Keun-Wook Lee; Shun-Chang Jiao; Jorge León Chong; Roberto I López-Sanchez; Timothy Price; Oleg Gladkov; Oliver Stoss; Julie Hill; Vivian Ng; Michaela Lehle; Marlene Thomas; Astrid Kiermaier; Josef Rüschoff
Journal:  Gastric Cancer       Date:  2014-07-20       Impact factor: 7.370

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.